
CureDuchenne Media Statement re:Phase III Clinical Trial Results for Drisapersen, GlaxoSmithKline/Prosensa TherapeuticÌ¢âÂã¢sTreatment for Duchenne Muscular Dystrophy
Background: GlaxoSmithKline (GSK) and Prosensa Therapeutics today announced the results of Phase III clinical data for drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy. The data […]
